行业分析 |
|
|
|
|
美国生物类似药的使用与医疗保险支付策略分析——基于Pfizer vs. Johnson案的思考 * |
董心月,蒋蓉,里扎·阿德列提别克,邵蓉() |
中国药科大学国家药物政策与医药产业经济研究中心 南京 211198 |
|
The Clinical Use and Insurance of Biosimilars in the US ——Taking the Pfizer vs. Johnson Lawsuit as an Example |
DONG Xin-yue,JIANG Rong,LIZHA Adelietibieke,SHAO Rong() |
The Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University, Nanjing 211198, China |
引用本文:
董心月,蒋蓉,里扎·阿德列提别克,邵蓉. 美国生物类似药的使用与医疗保险支付策略分析——基于Pfizer vs. Johnson案的思考 *[J]. 中国生物工程杂志, 2019, 39(12): 95-102.
DONG Xin-yue,JIANG Rong,LIZHA Adelietibieke,SHAO Rong. The Clinical Use and Insurance of Biosimilars in the US ——Taking the Pfizer vs. Johnson Lawsuit as an Example. China Biotechnology, 2019, 39(12): 95-102.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20191212
或
https://manu60.magtech.com.cn/biotech/CN/Y2019/V39/I12/95
|
[1] |
FDA. U . S. food & drug administration.[2018-12-04]..
|
[2] |
Sagonowsky E . With its Remicade biosimilar stymied by the brand, Pfizer sues Johnson & Johnson for ‘anticompetitive’ dealmaking. [2017-09-20/2018-12-01].
|
[3] |
Ashbridge B . Biosimilars council sides with Pfizer in Antitrust dispute with J&J. [2018-02-04/2018-12-03].
|
[4] |
Nicholas Simmons-Stern, Christina Danosi, Alexandra Haber , et al. The State of US Biosimilars Market Access: Payer Perceptions of Past, Present, and Future Hurdles to Adoption.[2018-01/2018-12]. .
|
[5] |
中国财经网. 辉瑞“起诉”强生不正当竞争. [2017-09-27/2018-11-30]. .
|
|
CFi.CN. Pfizer “Sues” Johnson for Unfair Competition. [2017-09-27/2018-11-30]. .
|
[6] |
医线 . 生物类似药研发势头大增,进入市场却受限制. [2016-04-01/2018-03-15]. .
|
|
Medical Line. R&D of Biosimilars Increased Dramatically, But the Marketing Access was Limited. [2016-04-01/2018-03-15]. .
|
[7] |
陈永法, 王翠玲, 伍琳 . 美国生物类似药研发与上市制度及对我国的启示. 中国医药工业杂志, 2016,47(10):1333-1338.
|
|
Chen Y F, Wang C L, Wu L . The research and development and the marketing approval system of the biosimilars in the United States and its enlightenment. Chinese Journal of Pharmaceuticals, 2016,47(10):1333-1338.
|
[8] |
Medicare.GOV. What Medicare Covers. [2018-12-04]..
|
[9] |
Brennan Z . Pfizer Sues J&J over contracts blocking Remicade biosimilars. [2017-09-20/2018-12-01].
|
[10] |
Shapland L . Inflectra launch: a medicare data perspective. [2018-01-21/2018-12-04].
|
[11] |
Silbersher Z . What are the takeaways from the Remicade? antitrust decision between Pfizer and J&J. [2018-08-16/2018-12-03].
|
[12] |
EY. Global biosimilar policy comparison.[2017-08-14/2019-01-14].
|
[13] |
Centers for Medicare and Medicaid Services . Medicare program; contract year 2019 policy and technical changes to the medicare advantage, medicare cost plan, medicare fee-for-service, the medicare prescription drug benefit programs, and the PACE program. Fed Regist, 2017,82(227):56336-56527.
|
[14] |
Rockoff J D . Pfizer plans to launch remicade biosimilar in november. [2016-10/2018-12].The Wall Street Journal. .
|
[15] |
CRS. Biologics and Biosimilars: Background and Key Issues.[2017-12-27/2018-12-03].
|
|
c4c4f5c.pdf.
|
[16] |
朗迦 . “捆绑销售”都是垄断吗. 经济世界, 2001,8(12):12-13.
|
|
Lang J . Are bundled sales monopolies. Business World, 2001,8(12):12-13.
|
[17] |
Abrams L W . Biosimilars & exclusive dealing antitrust law: Pfizer (Inflectra) v J&J (Remicade). [2017-10-30/2018-12-01].
|
[18] |
Davio K . Biosimilars Council Backs Pfizer with amicus brief in ongoing infliximab case. [2018-01-29/2018-12-01].
|
[19] |
The Competition Bureau . Competition Bureau statement regarding its inquiry into alleged anti-competitive conduct by Janssen. [2019-02-20/2019-04-05]..
|
[20] |
Southey F . Motion to dismiss Inflectra case denied, but J&J insists ‘Pfizer’s lawsuit is without merit’. [2018-08-14/2018-12-04].
|
[21] |
Hovenkamp H J, Hovenkamp E N . Complex bundled discounts and antitrust policy, Buffalo Law Review, 2009,57(3):1227-1249.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|